R&D Pipeline

 

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions. 

Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.

Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Skin Cancer
1L Metastatic Melanoma
Bempegaldesleukin + OPDIVO®
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
STUDY PIVOT-IO-001
+
Genitourinary Cancer
1L Metastatic Renal Cell Carcinoma
Bempegaldesleukin + OPDIVO®
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
STUDY PIVOT-09
+
Genitourinary Cancer
Muscle-Invasive Bladder Cancer Who Are Cisplatin Ineligible
Bempegaldesleukin + OPDIVO®
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
STUDY PIVOT-IO-009
+
Skin Cancer
Adjuvant Melanoma
Bempegaldesleukin + OPDIVO®
Phase 3 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
STUDY PIVOT-12
+
Head and Neck Cancer
1L Metastatic Head and Neck Squamous Cell Carcinoma
Bempegaldesleukin + KEYTRUDA®
Phase 3 Registrational
Agent(s) Bempegaldesleukin + KEYTRUDA®
STUDY PROPEL-36
+
Genitourinary Cancer
1L Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Cancer
Bempegaldesleukin + OPDIVO®
Phase 2 Registrational
Agent(s) Bempegaldesleukin + OPDIVO®
STUDY PIVOT-10
+
Genitourinary Cancer
1L Advanced Renal Cell Carcinoma
Bempegaldesleukin + OPDIVO® + TKI
Phase 2
Agent(s) Bempegaldesleukin + OPDIVO® + TKI
STUDY PIVOT-IO-11
+
Lung Cancer
1L Metastatic Non-Small Cell Lung Cancer
Bempegaldesleukin + KEYTRUDA®
Phase 2
Agent(s) Bempegaldesleukin + KEYTRUDA®
STUDY PROPEL
+
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Bempegaldesleukin + VB10.NEO
Phase 1
Agent(s) Bempegaldesleukin + VB10.NEO
STUDY DIRECT-01
+
Solid Tumors
Relapsed/Refractory Metastatic Melanoma
NKTR-262 + Bempegaldesleukin
Phase 1/2
Agent(s) NKTR-262 + Bempegaldesleukin
STUDY REVEAL
+
Hematological Cancer
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NKTR-255 + RITUXAN® or DARZALEX FASPRO®
Phase 1/2
Agent(s) NKTR-255 + RITUXAN® or DARZALEX FASPRO®
+
Solid Tumors
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
NKTR-255 + ERBITUX®
Phase 1/2
+
Autoimmune Disorders
Systemic Lupus Erythematosus
NKTR-358
Phase 2
Agent(s) NKTR-358
STUDY ISLAND-SLE
+
Autoimmune Disorders
Ulcerative Colitis
NKTR-358
Phase 2
Agent(s) NKTR-358
STUDY INSTRUCT-UC
+
Autoimmune Disorders
Psoriasis
NKTR-358
Phase 1B
Agent(s) NKTR-358
+
Autoimmune Disorders
Atopic Dermatitis
NKTR-358
Phase 1B
Agent(s) NKTR-358
+
Viral Diseases
COVID-19
Bempegaldesleukin
Phase 1
Agent(s) Bempegaldesleukin
+